ArticleFrontiers in public health2023
Carbapenem-resistant
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Root Cause Analysis for Outbreaks of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Risk prediction of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Treatment of central nervous system infections caused byFrontiers in medicine · 2026Review
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Comparison of antibiotic resistance, virulence determinants, and biofilm formation in Pseudomonas aeruginosa isolated from intestinal carriers and clinical samples.Folia microbiologica · 2025Article
- Coexistence of Multidrug Resistance and Hypervirulence-Associated Genes in Clinical Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Synthesis of the Pentasaccharide Unit of theMolecules (Basel, Switzerland) · 2025Article
- Phenotypic identification of Metallo-ß- lactamase resistance Gram negative bacteria from a clinical specimen in Sidama, Ethiopia.PloS one · 2025Article
- Incidence and Antibiotic Susceptibility of Gram-Negative Bacteria Associated With Chest Infections in Intensive Care Unit Patients From a Selected Hospital in the Kingdom of Saudi Arabia.BioMed research international · 2025Article
- High prevalence of carbapenem-resistantFrontiers in microbiology · 2025Article
- Occurrence of Plasmid-Mediated Quinolone Resistance and Carbapenemase-Encoding Genes inPathogens (Basel, Switzerland) · 2024Observational
- Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Molecular characterization of extensively drug-resistant hypervirulent Pseudomonas aeruginosa isolates in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Evaluated gene expressions of Metallo beta lactamase genes GIM and , VIM, SPM in Pseudomonas aeruginosa clinical isolates.Molecular biology reports · 2023Article
- The Prevalence of Metallo-Beta-Lactamese-(MβL)-ProducingMicroorganisms · 2023Review
- Evaluation and analysis of multidrug resistance- and hypervirulence-associated genes in carbapenem-resistantFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Carbapenem-resistant Methods: A retrospective case-control study of patients with Results: A total of 528 cases of Conclusions: Our findings provide insights into CRPA infections among critically ill children in China. They provide guidance in identifying patients that may be at high risk for a resistant infection and emphasize the importance of antimicrobial stewardship and infection control in hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.